MedTrace Logo

NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors

NCT04270461 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2020-10-22

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and clinical activity of NKG2D-based CAR-T cells infusion in the treatment of relapsed/refractory NKG2DL+ solid tumors.

Conditions

Interventions

BIOLOGICAL

NKG2D-based CAR T-cells

Autologous genetically modified anti-NKG2DLs CAR transduced T cells

Sponsors & Collaborators

  • KAEDI

    collaborator OTHER

  • Jiujiang University Affiliated Hospital

    lead OTHER_GOV

Principal Investigators

  • Changchun Cai · Affiliated hospital of jiujiang university

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-17
Primary Completion
2020-10-17
Completion
2020-10-17

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270461 on ClinicalTrials.gov